ClinicalTrials.gg

Program

TEV-53408

A development code. Also written as “TEV-53408 Dose A” and “TEV-53408 Dose B”.

Its studies are mostly in Vitiligo · Celiac Disease, led by Teva Pharmaceutical Industries.

Furthest: phase 3, since Oct 30, 20263 company-led studies, 3 open or runningNext primary completion: Apr 26, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Teva Pharmaceutical Industries33 open or runningphase 3since Oct 30, 2026Oct 1, 2024Apr 26, 2028phase 1 · NCT06625177

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 1, 2024First study: phase 1 study in VitiligoFirst studyNCT06625177 · 66 planned · United States
  2. Jan 29, 2025Phase 2 study in Celiac DiseaseNCT06807463 · 50 enrolled · United States, Australia, Finland
  3. Oct 30, 2026Phase 3 study in VitiligoPhase 3 reachedNCT07920211 · 1,020 planned

Ahead

  1. Apr 26, 2028Primary completion: phase 1 study in VitiligoNCT06625177
  2. Sep 12, 2030Primary completion: phase 3 study in VitiligoNCT07920211

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07920211Vitiligo3Not yet recruitingSep 12, 20301,020
NCT06807463Celiac Disease · United States, Australia, Finland2Active, not recruitingOct 2, 202650
NCT06625177Vitiligo · United States1RecruitingApr 26, 202866

How it is read

Names in the registry

  • “TEV-53408”, 2 entries
  • “TEV-53408 Dose A”, 1 entry
  • “TEV-53408 Dose B”, 1 entry

Codes read as this program: TEV53408.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.